[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Instituto de Investigación Sanitaria Gregorio Marañón\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":77},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100651551","clinical-impact-of-a-machine-learning-decision-support-system-for-empirical-antibiotic-therapy-100651551",false,"NCT07762378","Clinical Impact of a Machine Learning Decision Support System for Empirical Antibiotic Therapy","Clinical Impact of a Machine Learning Decision Support System for Empirical Antibiotic Therapy: A Prospective Quasi-Experimental Study","Inclusion Criteria:\n\n* Adult patients (aged ≥18 years)\n* Admitted to the Nephrology, Oncology or ICU wards\n* Diagnosis of sepsis, pneumonia and\u002For UTI\n* Empirical antibiotics prescribed\n\nExclusion Criteria:\n\n* informed consent obtained \\> 48 hours since the infection onset\n* beta-lactam allergy\n* infection syndrome other than sepsis, pneumonia or UTI\n* confirmed no-bacterial infection\n* death within the first 48 hours of inclusion or imminent risk of death at time of the inclusion\n* pregnancy and\u002For breastfeeding\n* inclusion in a clinical trial of antimicrobial treatment","ALL","18 Years",{"count":19,"type":20},486,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this quasi-experimental study is to analyze if a Machine Learning Clinical Decision Support System can improve the empirical antibiotic treatment in patients with pneumonia, urinary tract infection and \u002F or sepsis.\n\nThe main questions it aims to answer are:\n\n* Primary outcome: clinical success defined as clinical cure (resolution of all signs and symptoms related to infection); no complications until day 30 (recurrence, or development of adverse events- AEs-); no new acquisition of MDROs; and survival at day 30.\n* Secondary outcomes: a subgroup analysis of the primary outcome according to the department participants, infectious syndrome, severity of the infection assessed by the SOFA score, and in microbiological confirmed infections. In microbiological confirmed infections, desirability of Outcome Ranking (DOOR) for the Management of Antimicrobial Therapy (MAT) according to the beta-lactam classification\n\nResearchers will compare a pre-intervention group with a post-intervention to see if improve in the DOOR MAT score\n\nParticipants in the post-intervention group will:\n\n• Received empirical antibiotic therapy prescribed by their treating physicians according to the machine-learning recommendations",[26,27,28],"Pneumonia - Bacterial","Urinary Tract Infection Bacterial","Bloodstream Infection",[30,31,32,33,34],"antibiotics","empiric therapy","clinical decision support system","multidrug resistant microorganism","antimicrobial stewardship","NOT_YET_RECRUITING","2026-08-08",{"date":38,"type":39},"2026-08-13","ACTUAL",{"date":41,"type":20},"2026-09",{"date":43,"type":20},"2027-09",{"name":45,"class":46},"Instituto de Investigación Sanitaria Gregorio Marañón","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":57,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100641723","combination-vs-monotherapy-for-stenotrophomonas-maltophilia-infections-100641723","NCT07593547","Combination vs. Monotherapy for Stenotrophomonas Maltophilia Infections","Combination vs. Monotherapy for Stenotrophomonas Maltophilia Infections: A Multicentre Study Using Target Trial Emulation","EMULATE-Sm","Inclusion Criteria:\n\n* Adult patients\n* S. maltophilia infections\n* Different episodes if a new infection ocurred \\> 30 days since the index episode\n\nExclusion Criteria:\n\n* isolates obtained from patients outside of hospital admission\n* microbiological or clinical colonization\n* hospitalizations shorter than 72 hours since the time zero\n* patients who died in the first 72 hours since the time zero or who were in imminent risk of death\n* polymicrobial infections\n* receipt of inappropriate therapy after the time of the emulated randomization, defined as the absence of in vitro active antimicrobials or the administration of active antimicrobials for less than 48 hours\n* absence of data outcomes",{"count":56,"type":20},790,"60 Days","OBSERVATIONAL","The goal of this multicentre observational study is to analyse the treatment strategies and the outcomes for patients with S. maltophilia infections using target trial emulation methodology. The main question it aims to answer is:\n\n• Does combined therapy achieve better results than monotherapy in treating S. maltophilia infections?\n\nResearchers will compare groups receiving monotherapy and combined therapy to see if there are differences in all-cause 30-day mortality.",[28,26,61],"S Maltophilia Infections",[63,64,65,66],"S. maltophilia","Infection","Mortality","Combined therapy","RECRUITING","2026-06-14",{"date":70,"type":39},"2026-06-16",{"date":72,"type":39},"2026-03-06",{"date":74,"type":20},"2026-12-31",{"name":45,"class":46},1,""]